Neuroendocrine Tumors: Timely Diagnosis and Optimal Intervention
|
|
Accreditation Statement
|
|
The views expressed herein, while consistent with current medical literature, are solely those of the faculty.
The American Gastroenterological Association (AGA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The AGA designates this educational activity for a maximum of 1.5 credit hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
All presenters participating in continuing medical education programs sponsored by the AGA are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation. In addition, presenters and moderators are asked to make a reasonable effort to identify for the program audience any discussion of off-label or investigative use or application of a product or device that may occur during the educational presentation.
Funding for the development and production of the Neuroendocrine Tumors: Timely Diagnosis and Optimal Intervention multimedia module was provided through an unrestricted educational grant from Novartis Pharmaceuticals Corporation.
|
|
|
Purpose
|
|
|
Neuroendocrine Tumors (NET) are intrinsically hard to diagnose, and this can cause significant delays to proper treatment. Nevertheless, appropriate surgical and medical management options do exist and can, in many cases, vastly increase survival time and improve quality of life for patients. Physicians who treat patients with NET must remain up to date in the diagnosis, imaging and management (both surgical and medical) of these neoplasias.
|
|
|
Program Overview
|
|
|
This program discusses the diagnosis and the management of NET and highlights newer medical therapies that are being added to the armamentarium. Major symptomatology, laboratory tests and biomarkers, and imaging options are reviewed, including the use of radiolabeled congeners of natural ligands. The surgical options are overviewed and the two major biotherapies are featured. The impact of hormonal symptoms' control on the quality of life of patients suffering from indolent tumors is analyzed.
|
|
|
Audience
|
|
|
This program has been specifically developed to update and educate gastroenterologists and primary care physicians who provide care for people with NET.
|
|
|
Learning Objectives
|
- Discuss the challenges posed by the early diagnosis of NET and the advantages for the patient when a timely diagnosis is achieved
- Describe the major biomarkers/laboratory tests that are the most useful for the diagnosis of NET
- Identify the surgical options available for NET management
- Discuss the strengths and weaknesses of the biotherapies currently available for medical management of NET
|
|
|
Faculty
|
|
|
Lowell Anthony, MD, Program Chair
Associate Professor of Medicine
Louisiana State University
>> Read Biography
Thomas O'Dorisio, MD
Professor of Internal Medicine and Endocrinology
University of Iowa
>> Read Biography
Richard Warner, MD
Associate Clinical Professor of Medicine
Mount Sinai School of Medicine
>> Read Biography
|
|
|
Faculty Disclosure Information
|
|
|
In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, faculty members for this activity were each asked to complete financial disclosure forms. Disclosures are provided below.
Lowell Anthony, MD
Speakers' Bureau: Novartis Pharmaceuticals Corporation
Research support: Mallinckrodt, Novartis Pharmaceuticals Corporation
Thomas O'Dorisio, MD
Lectures/Talks: Novartis Pharmaceuticals Corporation
Grant Support: Novartis Pharmaceuticals Corporation, Mallinckrodt
Speakers' Bureau: Novartis Pharmaceuticals Corporation
Richard Warner, MD
Speakers' Bureau: Member of National Panel of Lecturers of Novartis Pharmaceuticals Corporation
|
|
|
Program Segments
|
|
|
|
Topic Overview:
|
Diagnosis Of Neuroendocrine Tumors
|
| |
Key Clinical Issues:
What Is Carcinoid Syndrome? What Are The Classification And Roles Of Somatostatin Receptors In Normal Physiology And Pathology? What Are The Current And Future Uses Of Somatostatin Scintigraphy?
|
|
Topic Overview:
|
Management Of Neuroendocrine Tumors
|
| |
Key Clinical Issues:
What Are The Current Radiolabeled Somatostatin Congeners And What's On The Horizon? What Are The Current Biotherapies For The Management Of Neuroendocrine Tumors? What Is Cytoreductive Surgery And What Is Its Role In Neuroendocrine Tumor Management?
|
|
|
|
|
|
|
|
